Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis

Rheumatology Advances in Practice

Volumn 2, Issue 1, 2018, Pages 1-2

  Oke, Anuoluwapo R ^a   Wheater, Matthew ^a   Karydis, Ioannis ^a   Wallis, Dinny ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; B RAF KINASE; C REACTIVE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; IPILIMUMAB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEMBROLIZUMAB; PREDNISOLONE; PROGRAMMED DEATH 1 RECEPTOR; TRAMETINIB;

ADULT; ARTHRALGIA; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CLINICAL ARTICLE; DAS28; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOTHERAPY; INGUINAL LYMPH NODE; LIVER METASTASIS; MELANOMA; MIDDLE AGED; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; TENOSYNOVITIS; TREATMENT DURATION;

EID: 85059342745     PISSN: None     EISSN: 25141775     Source Type: Journal    
DOI: 10.1093/rap/rky001     Document Type: Article

References (8)

1. Babacan T, Türkbeyler IH, Balakan O et al. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it? Int J Rheum Dis 2017;20:398-401
2. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;2015:23-34
3. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med 2015;372:2521-32
4. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol 2017;69:687-99
5. Chan MM, Kefford RF, Carlino M, Clements A, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 2015;38:37-9
6. Cappelli LC, Gutierrez AK, Baer AN et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43-50
7. Cappelli LC, Naidoo J, Bingham CO 3rd, Shah AA. Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. Immunotherapy 2017;9:5-8
8. Kim ST, Tayar J, Suarez-Almazor M et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 2017;76:2061-4